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treatment therapy became more complex according to the 
guidelines.
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OBJECTIVE: Atypical antipsychotic agents are considered the
ﬁrst-line treatment of schizophrenia. Aim of present study was
to identify factors affecting the cost of schizophrenia treatment
with atypical antipsychotic agents. METHODS: A retrospective
database study was conducted in three public hospitals in Hong
Kong. Patients initiated on atypical antipsychotic agents (amisul-
pride, olanzapine, quetiapine and risperidone) between March
2003 and September 2003 for treatment of schizophrenia for at
least three months was recruited. Patient medical records were
reviewed for up to 12 months before and after initiation date of
the antipsychotic agents to retrieve baseline demographic and
clinical factors and health care resource utilization for schizo-
phrenia. A multiple regression model was used to identify demo-
graphic, clinical factors and choice of atypical antipsychotic
agents with signiﬁcant association to health care resource uti-
lization. RESULTS: Eighty-two patients were included in the
analysis. Thirty-four (41%) patients were male and mean age
was 43 ± 14 years. The mean cost per patient per month was
USD 431 ± 914 (1USD = 7.8HKD). Three factors were associ-
ated with direct medical cost of health care resource utilized: 1).
History of drug abuse (RR = 1.26; 95% CI = 1.05–1.52); 2).
prior use of depot antipsychotic (RR = 1.22; 95% CI =
1.05–1.42); and 3). previous duration of hospitalization before
initiation of atypical antipsychotic therapy (RR = 1.00; 95% CI
= 1.00–1.01). CONCLUSION: History of drug abuse, prior use
of depot antipsychotic, previous duration of hospitalization
appeared to be inﬂuential to direct medical cost of atypical
antipsychotic treatment. The choice of antipsychotic agents did
not appear to affect the cost of treatment.
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OBJECTIVE: To determine the cost-effectiveness (measured
using an incremental cost-utility ratio) of treating schizophrenia
patients with olanzapine versus risperidone, quetiapine, amisul-
pride, or oral typical antipsychotics. METHODS: European
SOHO is a 3-year, prospective, outpatient, observational study
associated with antipsychotic treatment in 10 European coun-
tries. Health care resource use and quality of life data (EuroQol
EQ-5D and UK population utility values) were collected at base-
line, 3, 6, and 12 months. UK health care costs were applied to
the resource use data for the 10 countries. Pair-wise incremental
costs and utilities were estimated between olanzapine-treated
patients and patients treated with each of the other oral antipsy-
chotics. Utility increments were used to estimate quality-adjusted
life-years (QALYs) gained. Incremental cost-utility ratios were
expressed as the additional cost per QALY gained. Bootstrap
replications provided an estimate of uncertainty. RESULTS: A
total of 10,972 patients were enrolled at baseline, 80% were eli-
gible for analyses at 12 months. Treatment with olanzapine is
more effective and less costly than quetiapine and amisulpride.
Treatment with olanzapine is more effective compared to treat-
ment with risperidone. The incremental cost is marginal. The
incremental cost-utility ratio was £5156 per additional QALY
gained. The bootstrap replications for the above comparisons
showed 100% of the replications falling below a £30,000 per
QALY threshold. Treatment with olanzapine is more effective
compared to treatment with oral typical antipsychotics. The
additional cost is marginal. The incremental cost-utility ratio 
for olanzapine versus oral typical treatment was £15,696 per
additional QALY gained. The bootstrap replications showed
97% of the replications below a $30,000 per QALY threshold.
CONCLUSIONS: Among SOHO patients, if a funding thresh-
old of £30,000 per QALY gained is assumed, olanzapine has a
high probability of being the most cost-effective treatment 
compared with atypical and oral typical antipsychotic 
medications.
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OBJECTIVES: To determine current neuroleptic drug utilization
patterns of ambulatory care schizophrenic patients in Germany.
METHODS: Analysis of routine prescription data for the years
2003/2004 of patients insured with the Techniker Krankenkasse
sickness fund (covering approximately 6-million insured persons
distributed across all German states) with a hospital diagnosis of
schizophrenia F20 (ICD-10) in 2003. RESULTS: In 2004, 3397
patients with schizophrenia received 28,434 prescriptions for
neuroleptic drugs. In total, 33.1% of prescriptions were for
typical, 66.9% for atypical neuroleptics. In total, 51.2% of
typical neuroleptics prescribed were high-potency, 48.8% low-
potency drugs. Olanzapine was the most frequently prescribed
atypical (26.5%), followed by Clozapine (21.1%), Risperidone
(19.2%), Quetiapine (14.5%), Amisulpride (11.9%), Ziprasi-
done (6.2%), and Zotepine (0.6%). Analysing prescriptions on
an individual patient level gave a similar picture. During a 12
month-period after their ﬁrst hospital stay in 2003, 1490 patients
(43.9%) were treated only with atypical neuroleptics, 555
patients (17.2%) were treated with an atypical plus a low-
potency typical neuroleptic as adjuvant therapy. In total, 280
patients (8.7%) received typical neuroleptics only and 245
patients (7.6%) were prescribed both high-potency typical and
atypical neuroleptics. The remaining patients received no ambu-
latory prescriptions for neuroleptics. Some of them may have
received drugs from hospital pharmacies which are not recorded
in the ambulatory prescription database. CONCLUSIONS:
Reaching 61% in 2003/2004, the proportion of schizophrenic
patients receiving atypical neuroleptic drugs as their main med-
ication in our study population is much higher than previously
thought and in the range of other western European countries.
However, the share of Clozapine is also much higher than in
most countries. Although this non-random sample is not repre-
sentative of the German population, major differences in pre-
scribing behaviour depending on a patient’s sickness fund are
